October 3rd 2023
Liquid biopsy is offering a noninvasive, real-time, and personalized approach to tumor assessment, and is already revolutionizing the field of clinical oncology.
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Biomarkers Being Identified for Improved Diagnosis of Nasopharyngeal Carcinoma Via Liquid Biopsy
June 21st 2019During an interview with <em>Targeted Oncology</em>, lead study author Dhruvajyoti Roy, PhD, the director of technology at Laboratory for Advanced Medicine, Inc., shared information about the study, commented on other liquid biopsy research presented by peers at ASCO and provided insight as to what these data mean for the future of cell-free DNA methylation.
Read More
Monitoring of ctDNA in Patients With Bladder Cancer Has Potential to Assist Therapy Selection
June 20th 2019By testing circulating tumor DNA at critical time points throughout neoadjuvant chemotherapy and cystectomy, clinicians may be able to better predict which patients with advanced bladder cancer would likely benefit from additional systemic therapies, according to results of a study published in the <em>Journal of Clinical Oncology</em>.
Read More
Liquid Biopsies May Ease Genomic Evaluation and Disease Management for NSCLC
June 10th 2019For detecting genetic drivers and molecular aberrations in patients with metastatic non–small cell lung cancer, performing biopsies with comprehensive cell-free DNA, or liquid biopsies, may be a viable substitute for tissue-based biopsies.
Read More
Kasi Highlights Potential Impact of Detecting Resistance Mechanisms With Liquid Biopsies
May 22nd 2019Pashtoon M. Kasi, MD, MBBS, MS, discussed the current role of liquid biopsies in patients with CRC, GI, and other types of cancers. He also highlights the advantages to making treatment decisions based on results from liquid biopsies.
Read More
Oxnard Examines Discordance With Liquid Biopsies in Cancer
May 17th 2019Geoffrey R. Oxnard, MD, discusses testing error underlying liquid biopsy discordance. He also highlights steps clinicians can take to optimize liquid biopsies and where he sees this evolving in the treatment landscape for patients with cancer.
Read More
Significantly higher response rates were seen in patients with <em>ALK</em>-positive non–small cell lung cancer who had been treated with at least 1 prior ALK tyrosine kinase inhibitor before receiving lorlatinib and who harbored an <em>ALK </em>resistance mutation compared with those who did not have an <em>ALK </em>mutation.
Read More
Study Solidifies Confidence in Liquid Biopsies for Faster Biomarker Detection in NSCLC, Expert Says
April 17th 2019In addition to confirming the utility of liquid biopsies to reliably detect guideline-recommended biomarkers in patients with stage IV NSCLC, findings from the NILE study also showed liquid biopsies have a quicker turnaround time compared with standard tissue-based assays, said senior study author Vassiliki A. Papadimitrakopoulou, MD.
Read More
Rizvi Discusses the Clinical Relevance of Plasma and Tumor TMB
April 3rd 2019Naiyer A. Rizvi, MD, explained, in a presentation at the European Society of Medical Oncology 2019 International Congress on Targeted Anticancer Therapies, that plasma assays for determining TMB are becoming more diagnostically relevant.
Read More
Study Confirms Utility of Liquid Biopsies for Biomarker Detection in NSCLC
February 28th 2019Guardant360—a 73-gene next-generation sequencing panel—detected all of the guideline-recommended biomarkers in patients newly diagnosed with metastatic non–small cell lung cancer at a similar rate, but in a faster turnaround time than tissue genotyping, according to data from the NILE study.
Read More
The Role of Liquid Biopsy in NSCLC Continues to Emerge
February 12th 2019In a presentation during the 2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care symposium, Bob T. Li, MD, MPH, explained ctDNA’s growing importance in lung cancer, given the disease’s challenging prognosis.
Read More